Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(40.0%)
Phase 2
2(40.0%)
Phase 3
1(20.0%)
5Total
N/A(2)
Phase 2(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06526039Phase 3Not Yet Recruiting

A Short Regimen for Rifampicin-resistant Isoniazid-susceptible TB

Role: collaborator

NCT04938323Phase 2Withdrawn

Prevention of Acute Respiratory Infection in Taiwanese Institutionalized Elderly

Role: collaborator

NCT04433195Not ApplicableUnknown

Xpert MTB/RIF Test in the Diagnosis of Pulmonary Tuberculosis

Role: collaborator

NCT01047592Phase 2Completed

Treatment of N-methyl-D-aspartate (NMDA) Enhancers for Schizophrenia

Role: lead

NCT01056458Not ApplicableUnknown

Auricular Acupressure for Perimenopausal Women With Anxiety

Role: lead

All 5 trials loaded